Precision Optics Corporation, Inc. (POCI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 27, 2026, reports on a material definitive agreement entered into by Precision Optics Corporation, Inc. The company, incorporated in Massachusetts and trading on The Nasdaq Stock Market under the symbol POCI, announced the closing of a public equity offering on March 30, 2026.
Key Financial Metrics and Transaction Details
- Offering Size: 2,777,777 shares of common stock sold at $3.60 per share.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 416,667 additional shares.
- Net Proceeds: Approximately $10.7 million expected upon full exercise of the over-allotment option, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Underwriting Costs: Discount of up to 6.5% of gross proceeds; expense reimbursement capped at $90,000.
- Representative's Warrants: Issued 159,722 warrants with an exercise price of $4.21 per share, exercisable from March 30, 2026, through March 27, 2031.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The primary material change is the increase in the company's share count and capitalization resulting from the issuance of new common stock and warrants. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The company intends to utilize the net proceeds for working capital and general corporate purposes. The offering was made pursuant to an effective Form S-3 registration statement.
Risks and Contingencies: The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification obligations. The Representative's Warrants were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 as an unregistered sale of equity securities.
Key Facts for Investor Verification
- Verify the final number of shares issued if the over-allotment option is partially or fully exercised.
- Confirm the exact net proceeds received after all transaction expenses are finalized.
- Review the dilution impact of the 159,722 Representative's Warrants on existing shareholders.
- Check subsequent filings for updates on the specific allocation of the $10.7 million in proceeds.